Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells

Journal of Cellular Physiology

Volumn 226, Issue 7, 2011, Pages 1889-1896

  Sivanandam, Arun ^a   Murthy, Shalini ^a   Chinnakannu, Kannagi ^a   Bai, V Uma ^a   Kim, Sahn Ho ^a   Barrack, Evelyn R ^a   Menon, Mani ^a   Reddy, G Prem Veer ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Androgen receptor; Calmodulin; Calpain; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CALMODULIN; CALPAIN;

ARTICLE; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTECTION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION;

ANTINEOPLASTIC AGENTS; CALCIMYCIN; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CALMODULIN; CALPAIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IONOPHORES; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; SULFONAMIDES; TIME FACTORS; TRANSFECTION; TRIFLUOPERAZINE;

EID: 79955007789     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22516     Document Type: Article

References (59)

1. Bai VU, Cifuentes E, Menon M, Barrack ER, Reddy GP. 2005. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. J Cell Physiol 204:381-387.
2. Barnes JA, Gomes AV. 1995. PEST sequences in calmodulin-binding proteins. Mol Cell Biochem 149-150:17-27.
3. Bhattacharyya RS, Krishnan AV, Swami S, Feldman D. 2006. Fulvestrant (ICI 182, 780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther 5:1539-1549.
4. Burnstein KL. 2005. Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy. J Cell Biochem 95:657-669.
5. Carafoli E, Molinari M. 1998. Calpain: A protease in search of a function? Biochem Biophys Res Commun 247:193-203.
6. Chen BB, Mallampalli RK. 2007. Calmodulin binds and stabilizes the regulatory enzyme, CTP: Phosphocholine cytidylyltransferase. J Biol Chem 282:33494-33506.
7. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
8. Chen H, Libertini SJ, Wang Y, Kung HJ, Ghosh P, Mudryj M. 2010. ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem 285:2368-2374.
9. Cifuentes E, Mataraza JM, Yoshida BA, Menon M, Sacks DB, Barrack ER, Reddy GP. 2004. Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells. Proc Natl Acad Sci USA 101:464-469.
10. Craven CJ, Whitehead B, Jones SK, Thulin E, Blackburn GM, Waltho JP. 1996. Complexes formed between calmodulin and the antagonists J-8 and TFP in solution. Biochemistry 35:10287-10299.
11. Crawford C, Willis AC, Gagnon J. 1987. The effects of autolysis on the structure of chicken calpain II. Biochem J 248:579-588.
12. de Boer W, Bolt J, Kuiper GG, Brinkmann AO, Mulder E. 1987. Analysis of steroid- and DNA-binding domains of the calf uterine androgen receptor by limited proteolysis. J Steroid Biochem 28:9-19.
13. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. 2008. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469-5477.
14. Dice JF. 1987. Molecular determinants of protein half-lives in eukaryotic cells. FASEB J 1:349-357.
15. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
16. Ford OH III, Gregory CW, Kim D, Smitherman AB, Mohler JL. 2003. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 170:1817-1821.
17. Gil-Parrado S, Fernandez-Montalvan A, Assfalg-Machleidt I, Popp O, Bestvater F, Holloschi A, Knoch TA, Auerswald EA, Welsh K, Reed JC, Fritz H, Fuentes-Prior P, Spiess E, Salvesen GS, Machleidt W. 2002. Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members. J Biol Chem 277:27217-27226.
18. Goll DE, Thompson VF, Li H, Wei W, Cong J. 2003. The calpain system. Physiol Rev 83:731-801.
19. Gong Y, Blok LJ, Perry JE, Lindzey JK, Tindall DJ. 1995. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 136:2172-2178.
20. Gregory CW, He B, Wilson EM. 2001. The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol 27:309-319.
21. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y. 2009. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305-2313.
22. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. 2005. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96:251-258.
23. Hidaka H, Sasaki Y, Tanaka T, Endo T, Ohno S, Fujii Y, Nagata T. 1981. N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation. Proc Natl Acad Sci USA 78:4354-4357.
24. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. 2009. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16-22.
25. Ito H, Hidaka H. 1983. Antitumor effect of a calmodulin antagonist on the growth of solid sarcoma-180. Cancer Lett 19:215-220.
26. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA: Cancer J Clin 59:225-249.
27. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO. 1991. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (Baltimore, MD) 5:1396-1404.
28. Kang Z, Pirskanen A, Janne OA, Palvimo JJ. 2002. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277:48366-48371.
29. Khorchid A, Ikura M. 2002. How calpain is activated by calcium. Nat Struct Biol 9:239-241.
30. Kobayashi Y, Miwa S, Merry DE, Kume A, Mei L, Doyu M, Sobue G. 1998. Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner. Biochem Biophys Res Commun 252:145-150.
31. LaFevre-Bernt MA, Ellerby LM. 2003. Kennedy's disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J Biol Chem 278:34918-34924.
32. Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR, Sun SY. 2010. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 285:16096-16104.
33. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M. 2007. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 67:9001-9005.
34. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C. 2002a. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 277:36570-36576.
35. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. 2002b. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21:4037-4048.
36. Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT. 2006. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci USA 103:15085-15090.
37. Magi-Galluzzi C, Murphy M, Cangi MG, Loda M. 1998. Proliferation, apoptosis and cell cycle regulation in prostatic carcinogenesis. Anal Quant Cytol Histol 20:343-350.
38. Molinari M, Anagli J, Carafoli E. 1995. PEST sequences do not influence substrate susceptibility to calpain proteolysis. J Biol Chem 270:2032-2035.
39. Osawa M, Swindells MB, Tanikawa J, Tanaka T, Mase T, Furuya T, Ikura M. 1998. Solution structure of calmodulin-W-7 complex: The basis of diversity in molecular recognition. J Mol Biol 276:165-176.
40. Osborn M, Weber K. 1980. Damage of cellular functions by trifluoperazine, a calmodulin-specific drug. Exp Cell Res 130:484-488.
41. Pajonk F, van Ophoven A, McBride WH. 2005. Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res 65:4836-4843.
42. Pelley RP, Chinnakannu K, Murthy S, Strickland FM, Menon M, Dou QP, Barrack ER, Reddy GP. 2006. Calmodulin-androgen receptor (AR) interaction: Calcium-dependent, calpain-mediated breakdown of AR in LNCaP prostate cancer cells. Cancer Res 66:11754-11762.
43. Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH, Sheng S. 2006. Regulatory processes affecting androgen receptor expression, stability, and function: Potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98:1408-1423.
44. Saido TC, Nagao S, Shiramine M, Tsukaguchi M, Yoshizawa T, Sorimachi H, Ito H, Tsuchiya T, Kawashima S, Suzuki K. 1994. Distinct kinetics of subunit autolysis in mammalian m-calpain activation. FEBS Lett 346:263-267.
45. Savino JA III, Evans JF, Rabinowitz D, Auborn KJ, Carter TH. 2006. Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol Cancer Ther 5:556-563.
46. Schollmeyer JE. 1988. Calpain II involvement in mitosis. Science (New York, NY) 240:911-913.
47. Seubert P, Baudry M, Dudek S, Lynch G. 1987. Calmodulin stimulates the degradation of brain spectrin by calpain. Synapse (New York, NY) 1:20-24.
48. Sheflin L, Keegan B, Zhang W, Spaulding SW. 2000. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276:144-150.
49. Shumway SD, Maki M, Miyamoto S. 1999. The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain. J Biol Chem 274:30874-30881.
50. Simental JA, Sar M, Lane MV, French FS, Wilson EM. 1991. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266:510-518.
51. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS. 2009. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15:39-47.
52. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ. 2002. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62:6606-6614.
53. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J. 1991. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189-193.
54. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406.
55. Wang KK, Villalobo A, Roufogalis BD. 1989. Calmodulin-binding proteins as calpain substrates. Biochem J 262:693-706.
56. Wilson EM, French FS. 1979. Effects of proteases and protease inhibitors on the 4.5 S and 8 S androgen receptor. J Biol Chem 254:6310-6319.
57. Yang H, Murthy S, Sarkar FH, Sheng S, Reddy GP, Dou QP. 2008. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Phys 217:569-576.
58. Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML, Balk SP. 2006. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169:682-696.
59. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013.